ESR1 and breast cancer: Interfering with the ER pathway using anti-estrogens (selective estrogen receptor modulators such as tamoxifen or selective estrogen downregulators such as fulvestrant) or through estrogen deprivation (e.g., aromatase inhibitors) increases the survival of ER-positive BC patients.